The Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) drugs in development market research report provides comprehensive information on the therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and features dormant and discontinued products.
GlobalData tracks 76 drugs in development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) by 70 companies/universities/institutes. The top development phase for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) is phase ii with 32 drugs in that stage. The Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline has 70 drugs in development by companies and six by universities/ institutes. Some of the companies in the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline products market are: Johnson & Johnson, Jiangsu Hengrui Medicine and UroGen Pharma.
The key targets in the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274), and Toll Like Receptor 8 (CD288 or TLR8).
The key mechanisms of action in the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with nine drugs in Phase III. The Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline products include 14 routes of administration with the top ROA being Intravesical and 18 key molecule types in the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline products market including Small Molecule, and Monoclonal Antibody.
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) overview
Non-Muscle-Invasive Bladder Cancer (NMIBC), also referred to as superficial bladder cancer, is a type of bladder cancer that is confined to the innermost lining of the bladder. Unlike muscle-invasive bladder cancer, which penetrates the muscle layer of the bladder wall, NMIBC stays within the lining and does not invade deeper layers or surrounding tissues. NMIBC is categorized into subtypes, primarily as carcinoma in situ (CIS), papillary tumors, and Ta/T1 tumors. CIS refers to flat, high-grade lesions that are confined to the mucosal surface, while papillary tumors grow as small, finger-like projections on the inner bladder lining. Ta tumors are limited to the innermost layer of the bladder lining, while T1 tumors have invaded into the connective tissue just beneath the lining but not into the muscle layer. This form of bladder cancer tends to recur despite treatment, making it a chronic condition that requires vigilant monitoring and periodic surveillance. However, it generally has a better prognosis than muscle-invasive bladder cancer.
For a complete picture of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
